BackSurrozen- Warrants (01/08/2026) Overview

Surrozen- Warrants (01/08/2026) EBIT

Surrozen- Warrants (01/08/2026)'s EBIT is $-45M, below the Healthcare sector average of $22B.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$50.18M
↑ 656.47% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

-$44.61M
↓ 72.04% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Surrozen- Warrants (01/08/2026) (SRZNW) FAQ

The latest EBIT for SRZNW is $-45M as of June 2026. That compares with $-26M in the prior-year period — down 72.0% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Surrozen- Warrants (01/08/2026)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, SRZNW's EBIT moved from $-26M to $-45M — a 72.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Surrozen- Warrants (01/08/2026)'s operating scale or balance-sheet position.

Against Healthcare companies, SRZNW currently prints $-45M for EBIT, while the sector average sits near $22B. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at Surrozen- Warrants (01/08/2026)'s growth, margins, and balance sheet.

A EBIT figure of $-45M for SRZNW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting SRZNW's EBIT ($-45M), review year-over-year change from $-26M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.